An observational study in Nasopharyngeal Neoplasms and Laryngeal Disease, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Ruijin Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Nasopharyngeal Neoplasms with a site in China — 22 open to participants now, 30 under way, 6 of them phase 3. Nasopharyngeal Neoplasms · China.
Among the 83 studies in Nasopharyngeal Neoplasms with a site in China, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is one of 6 that started in 2025, is one of 10 observational ones, reaches primary completion later than 15 of the 29 other live ones, and was the 80th registered.
226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.
Browse Nasopharyngeal Neoplasms studies →22 of the 83 studies in Nasopharyngeal Neoplasms with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18–70
Jiangxi Provincial Cancer Hospital · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Avenzo Therapeutics, Inc. · Sites in China, United States
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 42 · Phase 3 13 · Phase 4 1
First in 1995; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 225 across 33 observational studies indexed under Nasopharyngeal Neoplasms.
Median enrollment 100 across the 73 interventional studies, 836 across the 10 observational. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 83 have an industry lead sponsor. The 10 most frequent:
Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
Ruijin Hospital has 1 study filed under Nasopharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Nasopharyngeal Neoplasms with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05587374Phase 3Sun Yat-sen UniversityCadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) | 2027-08-01 |
| NCT06688175The First Affiliated Hospital of Xiamen UniversityIMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma | 2026-12-31 |
| NCT07326358Ruijin HospitalAI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study | 2026-12-31 |
| NCT07552545Sun Yat-sen UniversityFull-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral Surgery | 2027-05-31 |
| NCT06802835Sun Yat-sen UniversityEGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 83 studies in Nasopharyngeal Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An artificial intelligence-assisted system is trained and validated by collecting nasopharyngolaryngoscopy images from patients.
To address the clinical pain points of traditional nasopharyngolaryngoscopy, such as incomplete visualization, inaccurate identification, and unclear imaging, this study will retrospectively collect nasopharyngolaryngoscopy images and baseline information (including gender and age) of patients who underwent nasopharyngolaryngoscopy at participating centers for model training and validation. Deep learning algorithms will be applied to construct the model. The final clinical performance evaluation of the model will be conducted using an independent, prospectively collected test cohort.
Image data of patients who underwent nasopharyngolaryngoscopy and met the research requirements were collected from various sub-centers nationwide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A deep learning model is trained using the training dataset and validated with the internal validation set.
Other: Diagnostic
Patients are prospectively enrolled, nasopharyngolaryngoscopy examination videos are collected, and the video data are processed to form a prospective test dataset, which is then used for testing.
Other: Diagnostic
The deep learning model is trained using the training dataset and tested with the internal validation set.
The prospective dataset is used for the comparative testing of the model and physicians.
performance of lesion detection
The area under the receiver operating characteristic curve (ROC-AUC) of the model for abnormal lesion detection
Time frame: Within 3 months after the completion of prospective data collection
performance of anatomic site recognition
The average precision (AP) of the model for recognizing nasopharyngeal and laryngeal anatomic sites
Time frame: Within 3 months after the completion of prospective data collection
Comparison of diagnostic performance between the model and physicians
Differences in sensitivity, specificity, and overall accuracy between the AI model and endoscopists with different years of experience
Time frame: Within 3 months after the completion of prospective data collection
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.